<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403636</url>
  </required_header>
  <id_info>
    <org_study_id>ARD12130</org_study_id>
    <secondary_id>2011-001616-57</secondary_id>
    <secondary_id>U1111-1118-6417</secondary_id>
    <nct_id>NCT01403636</nct_id>
  </id_info>
  <brief_title>A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia</brief_title>
  <official_title>A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      - To evaluate the efficacy of SAR245409 as determined by the objective response rate (ORR) in
      patients with 1 of following relapsed or refractory lymphoma or leukemia subtypes: mantle
      cell lymphoma (MCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL)/small
      lymphocytic lymphoma (SLL), or diffuse large B cell lymphoma (DLBCL)

      Secondary Objectives:

        -  To assess duration of response, progression free survival (PFS), and proportion of
           patients with PFS at 6 months (24 weeks) in patients with either MCL, FL, CLL/SLL or
           DLBCL treated with SAR245409

        -  To evaluate the safety and tolerability of SAR245409 in patients with MCL, FL, CLL/SLL
           or DLBCL

        -  To further characterize the plasma pharmacokinetics (PK) of SAR245409 in patients with
           MCL, FL, CLL/SLL or DLBCL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a 21 day screening period followed by 28 day cycles. Patients will continue to
      receive SAR245409 as long as there is clinical benefit or until a study withdrawal criterion
      is met. The last posttreatment visit will be 30 days after the last dose or until IMP-related
      toxicities have resolved or are deemed irreversible, whichever is later.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) as defined as the proportion of patients who experience complete response/remission (CR) or partial response/remission (PR)</measure>
    <time_frame>2 months to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) at 6 months</measure>
    <time_frame>6 months to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>mantle cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg twice daily: no eating for 2 hours prior and 1 hour after dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>follicular lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg twice daily: no eating for 2 hours prior and 1 hour after dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLL/SLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg twice daily:no eating for 2 hours prior and 1 hour after dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diffuse large B cell lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg twice daily:no eating for 2 hours prior and 1 hour after dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR245409</intervention_name>
    <description>Pharmaceutical form:capsule Route of administration: oral</description>
    <arm_group_label>mantle cell</arm_group_label>
    <arm_group_label>follicular lymphoma</arm_group_label>
    <arm_group_label>CLL/SLL</arm_group_label>
    <arm_group_label>Diffuse large B cell lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Tissue from an archived or fresh tumor sample

          -  A peripheral blood buffy coat sample is required for CLL/SLL.

          -  Patient has mantle cell lymphoma (MCL), follicular lymphoma (FL), or chronic
             lymphocytic leukemia (CLL)/SLL or diffuse large B cell lymphoma

          -  Patient &gt; or = 18 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; or = 2. Patients with
             DLBCL will have ECOG &lt; or = 1

          -  Adequate white blood cells and hemoglobin

          -  Good kidney and liver function

          -  Fasting glucose &lt; 160 mg/dL

          -  No other malignancy

          -  Use of adequate birth control

        Exclusion criteria:

          -  Treatment with cytotoxic chemotherapy, biologic agents, investigational therapies
             within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks of study enrollment

          -  Treatment with a small-molecule kinase inhibitor within 2 weeks, or 5 half lives of
             the drug or its active metabolites (whichever is longer) of study enrollment

          -  Prior treatment with a PI3K, mTOR, or Akt inhibitor. Prior treatment of MCL with
             temsirolimus is permitted in patients enrolled from countries where it is licensed for
             this indication.

          -  Radiation therapy within 2 weeks of enrollment

          -  Autologous stem cell transplantation within 16 weeks of enrollment

          -  Prior allogeneic transplantation except for patients with R/R DLBCL who meet inclusion
             criteria

          -  Central nervous system (CNS) or leptomeningeal involvement. Patients with DLBCL may
             have active CNS or leptomeningeal involvement.

          -  Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (anti-HCV)
             serology

          -  Primary CNS lymphoma

          -  Primary mediastinal B-lymphoma

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840012</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840104</name>
      <address>
        <city>Fort Meyers</city>
        <state>Florida</state>
        <zip>33919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840011</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840010</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840013</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840015</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840014</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036002</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036001</name>
      <address>
        <city>Hobart</city>
        <zip>7001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036005</name>
      <address>
        <city>Kingswood</city>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036003</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056003</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056002</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250004</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250005</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250003</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276003</name>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276002</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528001</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528003</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528002</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <disposition_first_submitted>February 17, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 17, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 17, 2016</disposition_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

